| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.0036 | 1 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.003 | 1 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0023 | 1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0016 | 1 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.003 | 1 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |